Why is Parmax Pharma falling/rising?

18 hours ago

Share Via

On 11-Dec, Parmax Pharma Ltd experienced a sharp decline in its share price, falling 13.72% to close at ₹29.67. This significant drop reflects a continuation of the stock’s underperformance relative to broader market benchmarks and heightened intraday volatility.

Steep Decline Against Market Benchmarks

Parmax Pharma’s recent price movement starkly contrasts with the broader market’s trajectory. Over the past week, the stock has declined by 13.93%, while the Sensex has remained nearly flat, registering a marginal loss of 0.52%. This divergence extends over longer periods as well, with the stock down 12.68% in the last month compared to a 1.13% gain in the Sensex. Year-to-date, Parmax Pharma’s losses deepen to 32.95%, whereas the benchmark index has appreciated by 8.55%. Even over a one-year horizon, the stock has fallen by 30.22%, while the Sensex has gained 4.04%. These figures highlight a sustained underperformance that has persisted for several years, with the stock lagging the Sensex’s 36.40% gain over three years and 83.99% over five years.

Intraday Volatility and Trading Patterns

On 11-Dec, the stock experienced high volatility, with an intraday price range of Rs 4.72 and an intraday volatility of 7.37%. The weighted average price indicates that a greater volume of shares traded closer to the day’s low, suggesting selling pressure dominated throughout the session. This selling momentum was further underscored by the stock’s failure to sustain gains after two consecutive days of upward movement, marking a clear trend reversal.

Technical Indicators and Moving Averages

Technically, Parmax Pharma is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning typically signals a bearish trend and may deter short-term and long-term investors alike. The inability to breach these resistance levels reinforces the negative sentiment surrounding the stock.

Declining Investor Participation and Liquidity

Investor engagement appears to be waning, as evidenced by a sharp 58.9% drop in delivery volume on 10-Dec compared to the five-day average. This decline in participation may reflect reduced confidence or interest in the stock, further exacerbating downward price pressure. Despite this, the stock remains sufficiently liquid for trading, with average traded value supporting reasonable trade sizes.

Sector Underperformance and Relative Weakness

Parmax Pharma’s performance today notably underperformed its sector by 14.65%, indicating that the stock is facing more severe headwinds than its industry peers. This relative weakness could be attributed to company-specific factors or broader concerns impacting investor sentiment towards Parmax Pharma.

Outlook and Investor Considerations

Given the persistent underperformance relative to the Sensex and sector, combined with technical weakness and declining investor participation, Parmax Pharma’s stock appears to be under significant pressure. The sharp intraday fall on 11-Dec and the failure to maintain recent gains suggest that investors remain cautious. Those holding the stock may need to monitor technical levels closely and consider the broader market context before making further investment decisions. Conversely, investors seeking exposure to the pharmaceutical sector might explore alternatives with stronger momentum and more favourable trading patterns.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE